adipiplon adipiplon adipiplon (developmental code name ng2-73) is an anxiolytic drug developed by neurogen corporation. it has similar effects to benzodiazepine drugs, but is structurally distinct and so is classed as a nonbenzodiazepine anxiolytic. not to be confused with adipiodone. adipiplonclinical dataroutes ofadministrationoralatc codenonelegal statuslegal status in general: uncontrolled identifiers iupac name 7--2-methyl-8-propyl-triazolopyrimidine cas number840486-93-3 nchemspider9373993 yuniiopl214poj1keggd08840 ychemblchembl2103791 ncomptox dashboard (epa)dtxsid40232944 chemical and physical dataformulac18h18fn7molar mass351.389 g·mol−13d model (jsmol)interactive image smiles n4c(c)nc1n4cnc(c1ccc)cn2ccnc2-c3ncccc3f inchi inchi=1s/c18h18fn7/c1-3-5-13-15(22-11-26-17(13)23-12(2)24-26)10-25-9-8-21-18(25)16-14(19)6-4-7-20-16/h4,6-9,11h,3,5,10h2,1-2h3 ykey:uamaihoeglexsv-uhfffaoysa-n y ny (what is this?) (verify) adipiplon is a subtype-selective gabaa receptor partial agonist, which binds preferentially to the α3 subtype. this is significant as while several previous nonbenzodiazepine drugs have been developed that are selective for α2/3 over the other subtypes, adipiplon is one of the first drugs selected for clinical development which is able to discriminate between α2 and α3, as well as showing little affinity for the α1 or α5 subtypes - alpidem is selective for α3 over α2, but still has moderate affinity for α1, whereas adipiplon is highly α3-selective with little affinity for either α1, α2 or α5. adipiplon is being researched as a potential medication for the treatment of anxiety and insomnia, and in 2008 it was being used in phase iib trials. these trials were suspended after significant next-day side effects were discovered.